This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
17 Apr 2013

T2 Biosystems makes advancements in hemostasis direct detection program

T2 Biosystems has announced progress in its hemostasis. product development program

T2 Biosystems haas announced advancements in its hemostasis direct detection program for T2HemoStat, which identifies physical changes in a blood sample such as coagulation fibrinolysis.
T2HemoStat can also detect changes in platelet function from small volumes of whole blood or plasma on a single compact instrument.
John McDonough, president and chief executive of T2 Biosystems, explained how T2HemoStat
might rapidly detect impaired hemostasis directly from whole blood.
"The issuance of new intellectual property and the impending presentation and publication of T2HemoStat data demonstrate the substantial progress of our program," he said.
A statement, issued by T2 Biosystems yesterday (April 16th), also revealed the group would be disclosing new data at multiple upcoming venues at key conferences and in journal publications.
These presentations are set to shed light on the benefits of T2HemoStat in the detection of clotting time and platelet function.
Mr McDonough joined the company in 2007, having previously held the position of president at Cytyc Development Corporation.

 

Related News